This clinical trial is focused on studying a condition known as Clostridioides difficile infection, often referred to as CDI. This infection can cause severe diarrhea and other intestinal issues. The study is testing a new treatment called VE303, which is a capsule containing live bacteria that are believed to help restore balance in the gut. The trial will compare the effects of VE303 with a placebo, which looks like the VE303 capsule but does not contain any active bacteria.

The purpose of the study is to see if VE303 can prevent the recurrence of CDI. Participants in the study will be randomly assigned to receive either VE303 or the placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. The treatment will be taken orally, and the study will last for several weeks, with follow-up checks to monitor the participants’ health and any recurrence of the infection.

Throughout the study, participants will be asked to attend regular visits, provide samples, and complete questionnaires to help researchers gather data on the effectiveness of VE303. The main goal is to determine if VE303 can reduce the rate of CDI recurrence by the end of the study period. Participants’ health and any side effects will be closely monitored to ensure safety and gather comprehensive results.